53 related articles for article (PubMed ID: 26554657)
1. The impact of Ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer.
Ocak B; Atalay FÖ; Sahin AB; Ozsen M; Dakiki B; Türe S; Mesohorli M; Odman HU; Tanrıverdi Ö; Ocakoğlu G; Bayrak M; Ozan H; Demiröz C; Sali S; Orhan SO; Deligönül A; Cubukcu E; Evrensel T
Bosn J Basic Med Sci; 2021 Feb; 21(5):549-554. PubMed ID: 33714260
[TBL] [Abstract][Full Text] [Related]
2. Predictive Modeling: A New Paradigm for Managing Endometrial Cancer.
Bendifallah S; Daraï E; Ballester M
Ann Surg Oncol; 2016 Mar; 23(3):975-88. PubMed ID: 26577116
[TBL] [Abstract][Full Text] [Related]
3. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
Ray-Coquard I; Monk BJ; Lorusso D; Mahdi H; Upadhyay V; Graul R; Husain A; Mirza MR; Slomovitz B
Int J Gynecol Cancer; 2023 Dec; 33(12):1943-1949. PubMed ID: 37907262
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
Collins A; Miles GJ; Wood J; MacFarlane M; Pritchard C; Moss E
Gynecol Oncol; 2020 Jan; 156(1):251-259. PubMed ID: 31767187
[TBL] [Abstract][Full Text] [Related]
5. Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
Ikeda Y; Oda K; Ishihara H; Wada-Hiraike O; Miyasaka A; Kashiyama T; Inaba K; Fukuda T; Sone K; Matsumoto Y; Arimoto T; Maeda D; Ikemura M; Fukayama M; Kawana K; Yano T; Aoki D; Osuga Y; Fujii T
Br J Cancer; 2015 Nov; 113(10):1477-83. PubMed ID: 26554657
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator.
Shih HC; Shiozawa T; Kato K; Imai T; Miyamoto T; Uchikawa J; Nikaido T; Konishi I
Hum Pathol; 2003 May; 34(5):471-8. PubMed ID: 12792921
[TBL] [Abstract][Full Text] [Related]
7. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Edqvist PH; Huvila J; Forsström B; Talve L; Carpén O; Salvesen HB; Krakstad C; Grénman S; Johannesson H; Ljungqvist O; Uhlén M; Pontén F; Auranen A
Gynecol Oncol; 2015 Jun; 137(3):529-37. PubMed ID: 25858696
[TBL] [Abstract][Full Text] [Related]
8. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
9. [The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].
Gottwald L; Kubiak R; Sek P; Piekarski J; Szwalski J; Pasz-Walczak G; Spych M; Suzin J; Tylińskis W; Jeziorski A
Ginekol Pol; 2013 Jun; 84(6):444-9. PubMed ID: 24032262
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
11. Cancer statistics, 2015.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2015; 65(1):5-29. PubMed ID: 25559415
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.
Ikeda Y; Oda K; Hiraike-Wada O; Koso T; Miyasaka A; Kashiyama T; Tanikawa M; Sone K; Nagasaka K; Maeda D; Kawana K; Nakagawa S; Fukayama M; Tetsu O; Fujii T; Yano T; Kozuma S
Oncol Rep; 2013 Aug; 30(2):584-8. PubMed ID: 23733133
[TBL] [Abstract][Full Text] [Related]
13. Markers for individualised therapy in endometrial carcinoma.
Salvesen HB; Haldorsen IS; Trovik J
Lancet Oncol; 2012 Aug; 13(8):e353-61. PubMed ID: 22846840
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
[TBL] [Abstract][Full Text] [Related]
15. Contemporary management of endometrial cancer.
Wright JD; Barrena Medel NI; Sehouli J; Fujiwara K; Herzog TJ
Lancet; 2012 Apr; 379(9823):1352-60. PubMed ID: 22444602
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
